• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Insmed (INSM)

Common Shares
Sell: $146.07|Buy: $146.65|Change: 6.66 (-4.34%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products.

Address

700 US Highway 202/206
Bridgewater
NJ
USA
08807

Telephone

+1 908 977-9900

Website

https://www.insmed.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Insmed Inc Fourth Quarter Earnings Conference Call for 20262027-02-19T08:00:00
Insmed Inc Fourth Quarter Earnings Results for 20262027-02-19T00:00:00
Insmed Inc Annual Report for 20262027-02-19T00:00:00
Insmed Inc Third Quarter Earnings Conference Call for 20262026-10-30T08:00:00
Insmed Inc Third Quarter Earnings Results for 20262026-10-30T00:00:00
Insmed Inc Second Quarter Earnings Conference Call for 20262026-08-07T08:00:00
Insmed Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Insmed Inc Annual General Meeting for 20262026-05-15T09:00:00
Insmed Inc First Quarter Earnings Conference Call for 20262026-05-08T08:00:00
Insmed Inc First Quarter Earnings Results for 20262026-05-08T00:00:00

Previous key dates

NameKey Date
Leerink Partners Global Healthcare Conference2026-03-10T08:00:00
46th Annual TD Cowen Healthcare Conference2026-03-02T09:50:00
Insmed Inc Fourth Quarter Earnings Conference Call for 20252026-02-19T08:00:00
Insmed Inc Fourth Quarter Earnings Results for 20252026-02-19T00:00:00
Insmed Inc Annual Report for 20252026-02-19T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T18:00:00
Evercore 8th Annual Healthcare Conference2025-12-02T11:15:00
Jefferies Global Healthcare Conference2025-11-18T03:30:00
Insmed Inc Third Quarter Earnings Conference Call for 20252025-10-30T08:00:00
Insmed Inc Third Quarter Earnings Results for 20252025-10-30T00:00:00
Morgan Stanely 23rd Annual Global Healthcare Conference2025-09-09T16:50:00
Wells Fargo 2025 Healthcare Conference2025-09-05T08:00:00
Insmed Inc Second Quarter Earnings Conference Call for 20252025-08-07T08:00:00
Insmed Inc Second Quarter Earnings Result for 20252025-08-07T00:00:00
2025 Goldman Sachs Annual Global Healthcare Conference2025-06-11T09:20:00
Insmed Phase 2b Study of TPIP in PAH Topline Results2025-06-10T08:00:00
Insmed Inc Annual General Meeting for 20252025-05-15T09:00:00
BofA Securities 2025 Health Care Conference2025-05-13T14:20:00
Insmed Inc First Quarter Earnings Conference Call for 20252025-05-08T08:00:00
Insmed Inc First Quarter Earnings Results for 20252025-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.